Investigational drug · Phase 3
Ipatasertib
Also called: RO5532961, GDC-0068, RG7440
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
57
Any phase or sponsor naming "Ipatasertib"
First trial start
2018
Mar 30, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ipatasertib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Breast Cancer
- Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
- Ovarian Cancer
- Solid Tumors
- Cancer
Approved drugs for the same conditions: Breast cancer · Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Ipatasertib" as an intervention, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03424005 · 1,132 participants (planned) · Start Mar 30, 2018 · Primary completion Sep 30, 2030
Drug: Capecitabine; Atezolizumab and 21 more · For: Metastatic Breast Cancer
Sites: Duarte, California; Irvine, California; La Jolla, California · 55 sites in all
- Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03072238 · 1,101 participants · Start Jun 30, 2017 · Primary completion Mar 16, 2020
Drug: Ipatasertib; Abiraterone and 2 more · For: Metastatic Prostate Cancer
Sites: Chandler, Arizona; Scottsdale, Arizona; Duarte, California · 176 sites in all
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04589845 · 920 participants (planned) · Start Jan 18, 2021 · Primary completion Sep 25, 2032
Drug: Entrectinib; Entrectinib and 9 more · For: Solid Tumors
Sites: Goodyear, Arizona; Los Angeles, California; Newport Beach, California · 112 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03337724 · 579 participants · Start Jan 6, 2018 · Primary completion Jan 4, 2023
Drug: Ipatasertib; Paclitaxel and 1 more · For: Breast Cancer
Sites: La Jolla, California; Los Angeles, California; Newport Beach, California · 176 sites in all
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SitePivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03498521 · 529 participants · Start Jul 10, 2018 · Primary completion Feb 14, 2023
Drug: Alectinib; Vismodegib and 16 more · For: Cancer of Unknown Primary Site
Sites: Blacktown, Australia; St Leonards, Australia; South Brisbane, Australia · 125 sites in all
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyPivotal-lookingStatus unknown
Fondazione per la Medicina PersonalizzataAcademic, hospital or other
NCT04591431 · 400 participants · Start Oct 7, 2020 · Primary completion Dec 2024
Drug: Erlotinib; Trastuzumab and 24 more · For: Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer and 1 more
Sites: Ancona, Italy; Aviano, Italy; Bari, Italy · 37 sites in all
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04802759 · 316 participants (planned) · Start Jun 22, 2021 · Primary completion May 30, 2029
Drug: Giredestrant; Abemaciclib and 8 more · For: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Sites: Duarte, California; Irvine, California; San Francisco, California · 32 sites in all
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)Pivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03337698 · 314 participants · Start Dec 27, 2017 · Primary completion Oct 14, 2025
Drug: Atezolizumab; Cobimetinib and 15 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Las Vegas, Nevada; New York, New York; Cleveland, Ohio · 29 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A spotlight on PTEN alterations in prostate cancer: A narrative review.
Alaimo D, Di Costanzo F, Oltrecolli M, et al. · Crit Rev Oncol Hematol 2026
- AI-assisted molecular docking and molecular dynamics simulations for predicting off-target effects of AKT1 ATP-competitive inhibitors.
Huang J, Pan Y, Fan F, et al. · J Biomol Struct Dyn 2026
- CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas.
Balaguer-Lluna L, Resa-Parés C, Brstilo L, et al. · Cancer Chemother Pharmacol 2026
- Deciphering the Medicinal Chemistry Aspects of Akt Inhibitors for the Management of Cancer: Structure-Activity Relationship Frameworks, Landscapes, and Optimization Approaches.
Dhangar MS, Palkar MB · Chem Biodivers 2026
- Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2- Advanced Breast Cancer.
Lei L, Canning M, Sakach E, et al. · Drugs 2026
- Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.
Tiu C, Yau W, Silva D, et al. · Clin Cancer Res 2026
Also in development for Metastatic Breast Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- JSKN016Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
- LasofoxifeneAZU-101Phase 34 trials
Sermonix Pharmaceuticals Inc. · Metastatic Breast Cancer, Vulvo Vaginal Atrophy (VVA), Locally Advanced or Metastatic Breast Cancer
- TQB2930Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer
- TQB3616Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.